Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial

医学 人口 随机化 射频消融术 肝细胞癌 临床终点 胃肠病学 核医学 外科 随机对照试验 烧蚀 内科学 环境卫生
作者
Tae Hyun Kim,Young Hwan Koh,Bo Hyun Kim,Min Ju Kim,Ju Hee Lee,Boram Park,Joong‐Won Park
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:74 (3): 603-612 被引量:152
标识
DOI:10.1016/j.jhep.2020.09.026
摘要

Proton beam radiotherapy (PBT) has recently been applied to treat hepatocellular carcinoma (HCC); however, there is no randomized controlled trial-based evidence on its safety and efficacy. We compared the outcomes of PBT and radiofrequency ablation (RFA) in patients with recurrent/residual HCC (rHCC) in a phase III non-inferiority trial.Patients with rHCC (size <3 cm, number ≤2) were randomly assigned to receive PBT or RFA according to Child-Pugh score and tumor stage. After randomization, if the assigned treatment was technically infeasible, crossover was allowed. The primary endpoint was 2-year local progression-free survival (LPFS), with a non-inferiority margin of 15% in the per-protocol (PP) population; a complementary analysis was performed in the intention-to-treat (ITT) population (NCT01963429).The ITT population comprised 144 patients receiving either PBT (n = 72) or RFA (n = 72). Six patients switched from the PBT arm to the RFA arm and 19 patients switched from the RFA arm to the PBT arm. In the PP population, the 2-year LPFS rate with PBT (n = 80) vs. RFA (n = 56) was 94.8% vs. 83.9%, a difference of 10.9 percentage points (90% CI 1.8-20.0; p <0.001); in the ITT population, the 2-year LPFS rate with PBT vs. RFA was 92.8% vs. 83.2%, a difference of 9.6 percentage points (90% CI 0.7-18.4; p <0.001), meeting the criteria for non-inferiority. The 3- and 4-year LPFS rates for PBT were also non-inferior to those for RFA. The most common adverse events were radiation pneumonitis (32.5%) and decreased leukocyte counts (23.8%) for PBT and increased alanine aminotransferase levels (96.4%) and abdominal pain (30.4%) for RFA. No Grade 4 adverse events or mortality were noted.PBT showed LPFS values that were non-inferior to those for RFA; in addition, PBT was tolerable and safe. CLINICAL TRIAL NUMBER: #NCT01963429 (ClinicalTrials.gov).Radiofrequency ablation is the standard of care for patients with small hepatocellular carcinoma in whom surgery is not feasible. This study is the first phase III randomized controlled trial to evaluate the clinical outcomes of proton beam radiotherapy vs. radiofrequency ablation in patients with recurrent small HCC. Our findings show that this new technique is not inferior and can be applied safely in patients with small recurrent hepatocellular carcinoma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lyb完成签到 ,获得积分10
刚刚
风中方盒完成签到,获得积分20
刚刚
布丁圆团完成签到,获得积分10
1秒前
yikeshu完成签到,获得积分10
1秒前
Zoe完成签到 ,获得积分10
2秒前
4秒前
星辰大海应助do0采纳,获得10
5秒前
tt完成签到 ,获得积分10
6秒前
浅辰完成签到,获得积分10
7秒前
大气萤完成签到,获得积分20
8秒前
8秒前
我ppp完成签到 ,获得积分10
8秒前
9秒前
易燃物品完成签到,获得积分10
9秒前
Hello应助Ther采纳,获得10
11秒前
CherylZhao完成签到,获得积分10
12秒前
Galato发布了新的文献求助10
13秒前
颜愫完成签到,获得积分10
13秒前
安详向日葵完成签到 ,获得积分10
14秒前
拼搏的白云完成签到,获得积分10
14秒前
852应助hhh采纳,获得10
14秒前
李白白白完成签到,获得积分10
14秒前
王手完成签到,获得积分10
14秒前
15秒前
一人完成签到,获得积分10
16秒前
do0完成签到,获得积分10
17秒前
yar应助xlz110采纳,获得10
17秒前
NexusExplorer应助落寞凌波采纳,获得10
19秒前
量子星尘发布了新的文献求助10
22秒前
123完成签到 ,获得积分10
22秒前
哈哈呵完成签到,获得积分10
22秒前
22秒前
Rylee完成签到,获得积分10
22秒前
Jiro完成签到,获得积分10
24秒前
我ppp发布了新的文献求助60
25秒前
26秒前
纳米酶催化完成签到,获得积分10
27秒前
27秒前
John完成签到,获得积分10
27秒前
李小强完成签到,获得积分10
28秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029